Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actelion to acquire Ceptaris contingent upon Valchlor approval

Executive Summary

Just weeks ahead of the PDUFA date for its lead candidate Valchlor (mechlorethamine), private spec pharma Ceptaris Therapeutics Inc. has agreed to be acquired by Actelion US Holdings Co., a division of European biotech Actelion Pharmaceuticals Ltd., in a transaction that hinges upon the FDA’s approval of that drug for stage I-IIa mycosis fungoides, the most common form of a rare type of non-Hodgkin’s lymphoma called cutaneous T-cell lymphoma. Ceptaris will receive $25mm up front and another $225mm should the deal close. In addition, shareholders are entitled to undisclosed payments tied to Valchlor’s net sales and/or commercialization milestones.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies